Cargando…

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus

Dapagliflozin is an inhibitor of human renal sodium‐glucose cotransporter 2 (SGLT2), first approved for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9). The effect of UGT1A9 polymorphisms on dapaglif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naagaard, M. Daniel, Chang, Roy, Någård, Mats, Tang, Weifeng, Boulton, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305486/ https://www.ncbi.nlm.nih.gov/pubmed/34687551 http://dx.doi.org/10.1111/bcp.15117

Ejemplares similares

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
por: Jo, Heeseung, et al.
Publicado: (2021)

Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study
por: Någård, Mats, et al.
Publicado: (2020)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults
por: Någård, Mats, et al.
Publicado: (2020)

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
por: Sokolov, Victor, et al.
Publicado: (2018)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications
por: Patel, Divya, et al.
Publicado: (2019)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

Correlates of insulin clearance in apparently healthy non-obese Japanese men
por: Kaga, Hideyoshi, et al.
Publicado: (2017)

What do passwords and toothbrushes have in common?
por: Computer Security Team
Publicado: (2011)

Psychotherapies for PTSD: what do they have in common?
por: Schnyder, Ulrich, et al.
Publicado: (2015)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015)

Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man
por: Cerezo-Arias, María de las Olas, et al.
Publicado: (2022)

Introducing fuzziness into maximum common substructures for meaningful cluster characterisation
por: Herhaus, Christian
Publicado: (2014)

Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children
por: Du, Zhongliang, et al.
Publicado: (2016)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
por: Wolf, Vaneza Lira W., et al.
Publicado: (2021)

Historia de la UGT.
Publicado: (2008)

Predicting Flavonoid UGT Regioselectivity
por: Jackson, Rhydon, et al.
Publicado: (2011)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Conversations worth having: using appreciative inquiry to fuel productive and meaningful engagement
por: Stavros, Jacqueline M, et al.
Publicado: (2018)

Feeling of Meaningfulness and Anxiety of Taekwon-Do Fighters in a Salutogenic Notion
por: Ortenburger, Dorota, et al.
Publicado: (2022)

What do kidneys and embryonic fish skin have in common?
por: Williams, Ruth
Publicado: (2009)

Transgenic Common Carp Do Not Have the Ability to Expand Populations
por: Lian, Hao, et al.
Publicado: (2013)

Cardiac Regeneration and Tumor Growth—What Do They Have in Common?
por: Dicks, Severin, et al.
Publicado: (2020)

Bone Tissue and the Nervous System: What Do They Have in Common?
por: Minoia, Arianna, et al.
Publicado: (2022)

Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
por: Cure, Erkan, et al.
Publicado: (2020)

Activation of Alternative Bilirubin Clearance Pathways Partially Reduces Hyperbilirubinemia in a Mouse Model Lacking Functional Ugt1a1 Activity
por: Banerjee, Bhaswati, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_osk99co3e5fun6f3altp0vheoj